Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study

Conclusion: The PD-L1 expression was dynamic as tumor developed, which was valuable in selecting the proper type of sample for accurately evaluating the prognosis of using pembrolizumab as first or second line treatment.

Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Luqiao Luo, Xinlan Luo, Wendan Chen, Chunyan Liang, Su Yao, Weihong Huang, Chao Liu, Yan Ge, Xingtao Lin, Zhi Li Tags: Research Paper Source Type: research